FPP004X / FunPep - LARVOL DELTA

Announcement of Completion of Subject Enrollment in Phase I Clinical Trial of Allergy Vaccine [Google translation] (PR TIMES) - "This study will primarily evaluate the safety, tolerability, and immunogenicity (antibody production) of FPP004X when administered intramuscularly to healthy adults and patients with seasonal allergic rhinitis (hay fever)."

Enrollment closed • Immunology